The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Risk stratification model for asymptomatic Waldenström’s macroglobulinemia
Romanos Sklavenitis-Pistofidis, MD, Dana-Farber Cancer Institute, Boston, MA, describes a novel risk stratification model for asymptomatic Waldenström’s macroglobulinemia (WM), sharing some insights into the parameters in this model and statistics on its usage. Dr Sklavenitis-Pistofidis also highlights the importance of early intervention in asymptomatic WM, and the need to further research and integrate risk stratification models across cohorts of patients. To conclude, Dr Sklavenitis-Pistofidis explains how bone marrow immune profiling may provide insights into disease progression, and allow for better approaches to early intervention. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
